--- title: "Werewolf Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285659783.md" datetime: "2026-05-08T03:45:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285659783.md) - [en](https://longbridge.com/en/news/285659783.md) - [zh-HK](https://longbridge.com/zh-HK/news/285659783.md) --- # Werewolf Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.28, beating the estimate of USD -0.295. EBIT: As of FY2026 Q1, the actual value is USD -12.34 M. Werewolf Therapeutics, Inc. operates as a single reportable segment focused on the discovery and development of cancer therapeutics . #### Consolidated Financial Performance (Three Months Ended March 31, 2026 vs. 2025) - **Net Loss**: The company reported a net loss of - $13,532 thousand for the three months ended March 31, 2026, improving from - $18,089 thousand in the prior-year period . - **Operating Expenses**: Total operating expenses decreased to $13,271 thousand in 2026 from $17,991 thousand in 2025 . - **Research and Development (R&D) Expenses**: R&D expenses decreased by $4,939 thousand, from $13,120 thousand in 2025 to $8,181 thousand in 2026, primarily due to a reduction in force and curtailed spending . - **General and Administrative (G&A) Expenses**: G&A expenses increased by $219 thousand, from $4,871 thousand in 2025 to $5,090 thousand in 2026, mainly due to higher professional services fees . - **Operating Loss**: The operating loss was - $13,271 thousand in 2026, compared to - $17,991 thousand in 2025 . - **Interest Income**: Interest income decreased from $997 thousand in 2025 to $433 thousand in 2026 . - **Interest Expense**: Interest expense increased from - $1,263 thousand in 2025 to - $1,368 thousand in 2026 . - **Other Income, Net**: Other income, net, increased from $168 thousand in 2025 to $674 thousand in 2026 . #### Cash Flow (Three Months Ended March 31, 2026 vs. 2025) - **Net Cash Used in Operating Activities**: Net cash used in operating activities significantly decreased to - $10,597 thousand in 2026 from - $18,948 thousand in 2025, a reduction of $8,351 thousand, due to cost reduction efforts . - **Net Decrease in Cash, Cash Equivalents and Restricted Cash**: The total net decrease was - $10,597 thousand in 2026, compared to - $18,948 thousand in 2025 . #### Balance Sheet Highlights (As of March 31, 2026 vs. December 31, 2025) - **Cash and Cash Equivalents**: Cash and cash equivalents decreased from $57,050 thousand at December 31, 2025, to $46,450 thousand at March 31, 2026 . - **Accumulated Deficit**: The accumulated deficit increased to - $488,942 thousand at March 31, 2026, from - $475,410 thousand at December 31, 2025 . #### External Development Costs by Product Candidate (Three Months Ended March 31, 2026 vs. 2025) - **Total External Development Costs**: Total costs decreased to $3,376 thousand in 2026 from $6,927 thousand in 2025 . - **WTX-330**: Costs were $1,414 thousand in 2026, down from $1,454 thousand in 2025 . - **WTX-124**: Costs decreased significantly to $1,174 thousand in 2026 from $4,795 thousand in 2025 . - **WTX-1011**: Costs were $71 thousand in 2026, up from $0 thousand in 2025 . - **WTX-2022**: Costs were $50 thousand in 2026, up from $0 thousand in 2025 . - **WTX-712**: Costs decreased to $6 thousand in 2026 from $87 thousand in 2025 . - **WTX-921**: Costs were $0 thousand in 2026, down from $9 thousand in 2025 . - **WTX-518**: Costs were $0 thousand in 2026, down from $1 thousand in 2025 . - **Pre-development candidates**: Costs increased to $661 thousand in 2026 from $581 thousand in 2025 . #### Restructuring Costs (Three Months Ended March 31, 2026) - Werewolf Therapeutics, Inc. recognized $4,305 thousand in restructuring costs as part of the 2026 Restructuring plan . An additional $2,100 thousand in costs are estimated to complete the restructuring by the end of 2026 . #### Outlook and Strategy Werewolf Therapeutics, Inc. is exploring a full range of strategic alternatives, including a potential sale, business combination, asset sales, or licensing arrangements, to maximize stockholder value and advance its pipeline . The company anticipates that its existing cash and cash equivalents will be insufficient to fund operations for at least twelve months, indicating a need for additional capital through financing or strategic agreements . The Phase 1/1b clinical trial for WTX-124 and Part A of the Phase 1b/2 clinical trial for WTX-330 are expected to conclude in Q3 2026, with further development requiring additional funding and strategic partnerships . ### Related Stocks - [HOWL.US](https://longbridge.com/en/quote/HOWL.US.md) ## Related News & Research - [Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock](https://longbridge.com/en/news/287219594.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [REEVES CONFIRMS NO INCREASE IN UK FUEL DUTY IN 2026](https://longbridge.com/en/news/287213292.md)